Anxiolytic effect of midazolam premedication assessed by clinical and platelet aggregation profiles by Khan, Ehtesham I et al.
eCommons@AKU
Department of Anaesthesia Medical College, Pakistan
April 2010
Anxiolytic effect of midazolam premedication
assessed by clinical and platelet aggregation profiles
Ehtesham I Khan
Aga Khan University
Rehana S Kamal
Aga Khan University
Hameed Ullah
Aga Khan University
Follow this and additional works at: http://ecommons.aku.edu/pakistan_fhs_mc_anaesth
Part of the Anesthesia and Analgesia Commons, and the Surgery Commons
Recommended Citation
Khan, E., Kamal, R., Ullah, H. (2010). Anxiolytic effect of midazolam premedication assessed by clinical and platelet aggregation
profiles. Journal of Ayub Medical College, 22(2), 4-7.
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_anaesth/7
J Ayub Med Coll Abbottabad 2010;22(2) 
http://www.ayubmed.edu.pk/JAMC/PAST/22-2/Ehtesham.pdf  4 
ANXIOLYTIC EFFECT OF MIDAZOLAM PREMEDICATION ASSESSED 
BY CLINICAL AND PLATELET AGGREGATION PROFILES 
Ehtesham I. Khan, Rehana S. Kamal, Hameed Ullah 
Department of Anaesthesia & Intensive Care, Aga Khan University, Karachi, Pakistan 
Background: It is well documented that surgery is associated with increased anxiety, which has an 
adverse impact on patient’s outcome. This study was designed to assess the anxiolytic effect of 
midazolam in pre-anaesthetic medication by using clinical and platelet aggregation profiles. 
Methods: Sixty ASA I and II female patients aged between 35 and 60 years undergoing elective 
abdominal hysterectomy were randomly divided into two equal groups. Group I received placebo as 
pre-medication while group II received 0.15 mg/kg midazolam as pre-medication 1 hour 
preoperatively. They were monitored for visual analogue scale (VAS) for anxiety, observer’s anxiety 
criteria, sedation score, blood pressure, heart rate and platelet aggregation profile immediately before 
and 1 hour after pre-medication. Results: There was statistically significant difference with respect 
to VAS of anxiety, observer’s anxiety criteria, sedation scores, systolic and diastolic blood pressure 
(p<0.05). Heart rate was higher in the midazolam group but this was not statistically significant. 
There was no statistical significant difference in platelet aggregation profile in the two groups. 
Conclusion: Findings of the study suggest midazolam is a good anxiolytic for pre-medication and its 
effect on platelet aggregation profile needs to be further evaluated.  
Keywords: Pre-medication, Widazolam, Anxiolysis, Platelet aggregation
INTRODUCTION 
Preoperative anxiety is a challenging concept in the 
preoperative care of patients and almost all patients 
undergoing surgery experience varying level of 
anxiety.1 Anxiety is dependant upon the perceived 
threat and danger of the surgical procedure, pain, 
anaesthesia, outcome of surgery and worries about the 
family. Patients undergoing major surgery, i.e., major 
abdominal, thoracic and cardiac surgery and women 
have higher levels of anxiety.2 It has been 
demonstrated that women undergoing invasive 
radiological or surgical procedures for gynaecological 
disorders experience higher levels of state anxiety, 
express more worry, display greater heart rate and 
blood pressure changes before and during surgery, are 
more difficult to anaesthetise and are more likely to 
experience headache, vomiting and pain in the 
postoperative period.3,4 Relief of anxiety is thus a 
humane goal and should be attempted in every patient. 
Benzodiazepines are widely used as 
anxiolytics prior to surgery.5 Midazolam, a water 
soluble benzodiazepine is a useful agent for 
pre-medication and sedation. It has a short onset time 
and duration of action when compared to other 
benzodiazepines. In addition to anxiolysis, it also 
possesses hypnotic, anticonvulsant, muscle relaxant 
and antegrade amnestic properties.6 
Blood platelets, numbering 1.8–3.5×105/ml, 
circulate within the vasculature as disc shaped cells 
that are normally non-adherent to each other and to the 
endothelial cells that line the blood vessel wall. 
‘Platelet aggregation’ is a term used to denote the 
adherence of one platelet to another. Adding 
aggregating agent, e.g., adrenaline, noradrenaline, etc. 
to platelet rich plasma, which is being continually 
stirred, can induce this phenomenon. Induction of 
platelet aggregation by adrenaline presumably occurs 
through binding to specific receptor, suggested to be 
α-type, on platelet membrane.7 
Preoperative anxiety is associated with a rise 
in plasma catecholamine (adrenaline, noradrenaline) 
levels. This rise in adrenaline would result in 
enhanced platelet aggregation in anxiety states. 
Midazolam, an anxiolytic agent, would reduce the 
anxiety levels and corresponding catecholamine 
secretion. This will prevent the platelet aggregation 
in patients receiving midazolam as pre-medication. 
The objective of this study was to examine the 
anxiolytic effects of midazolam in a homogenous group 
of patient undergoing elective hysterectomy using 
cardiovascular variables, subjective anxiety and sedation 
scores and objectively by platelets aggregation profiles. 
MATERIAL AND METHODS 
After approval from Ethics Review Committee of the 
Aga Khan University and obtaining informed consent, 
a double blinded, randomized, placebo controlled 
trial was conducted on 60 ASA I and II female 
patients, aged between 35 and 60 years, scheduled for 
elective abdominal or vaginal hysterectomy. Patients 
with history of psychiatric illness, alcohol abuse, 
hypertension, ischemic heart disease, diabetes 
mellitus, patients receiving β-blockers and Ca++ 
channel blockers and those taking benzodiazepines 
since admission to hospital were excluded from the 
study. Patients were equally divided into two groups 
with patients in group I receiving placebo and 
group-II receiving midazolam 0.15 mg/kg orally as 
pre-medication 1 hour prior to the anaesthetic. The 
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pre-medication drug, either placebo or midazolam, 
was grinded and dissolved in sweet syrup to make the 
drug palatable. The final concentration of midazolam 
was 1 mg/ml and the mixture was prepared fresh for 
every patient. Appropriate amount of drug was given 
to the patient in the ward by a person not involved in 
taking observations. 
Following parameters were monitored 
immediately before and 1 hour after the 
administration of study drug: 
1 Visual analogue scale for anxiety in which 
patients were asked to grade their level of anxiety 
on a scale of 0–10 (0 being totally calm and 10 
being extremely anxious). 
2 Observer’s anxiety criteria, in this, the patient’s 
anxiety was assessed by the observer who was 
blinded to the type of medication given to the 
patient and was assessed on the following scale: 
Grade 1- Calm 
Grade 2- Mild anxiety 
Grade 3- Moderately anxious 
Grade 4- Extremely anxious. 
3 Sedation score was also assessed by the blinded 
observer who rated the patients sedation as: 
Grade 0: Fully awake, 
Grade 1: Awake but with signs of drowsiness, 
Grade 2: Asleep but responsive to spoken words, 
Grade 3: Asleep and unresponsive to spoken 
words and 
Grade 4: Asleep and unresponsive to gentle 
shaking. 
4 Systolic and diastolic blood pressure and heart 
rate was measured by using automated blood 
pressure and heart rate monitors.  
5 For platelet aggregation profile, the method used to 
quantitatively assess platelet aggregation was 
introduced by Born8 in 1962 and is based on the 
principle of light transmission through platelets rich 
plasma (PRP) caused by the formation of platelet 
aggregates and the volume occupied by the platelets 
in a photoelectric cell. In this study, 4.5 ml of 
venous blood was collected in a 5 ml syringe with a 
21 gauge needle. Blood was then gently transferred 
into a tube containing 0.5 ml of 3.8% sodium citrate 
which was mixed by gentle inversion and vigorous 
shaking was avoided. This process was done before 
and one hour after the pre-medication. The sample 
was taken to the pharmacology laboratory and PRP 
was prepared by centrifuging the sample at a speed 
of 1,100–15,000 RPM for 15 minutes (DYDAC II 
Clay Adams). PRP was withdrawn with a 
siliconised plastic pipette into a glass tube and was 
capped and labelled PRP. The platelet poor plasma 
(PPP) was prepared by re-centrifuging the 
remaining blood specimen at 4,000 RPM for 5 
minutes. The PPP was transferred into a plastic tube 
and was labelled platelet poor plasma. To study 
platelet aggregation Lumi Aggregometer model 
400 was used.  Epinephrine 200 mol was added 
to 0.45 ml of PRP, which was continually being 
stirred. As aggregation proceeded, platelet 
clumping occurred. This reduced the optical density 
of the PRP allowing more infrared light to pass 
through. The process was repeated for PPP. The 
Lumi Aggregometer developed voltage 
proportional to the difference between the PRP and 
PPP and this difference was recorded on the strip 
chart. Test was performed within an hour after the 
blood was drawn from the patient and efforts were 
made to keep the plasma at ambient temperature of 
37 ºC. 
All values given in the results are presented 
as mean with standard deviation (SD). Numerical 
data were analysed using the analysis of variants 
(ANOVA) and chi-square test where appropriate. A 
p-value of less than 0.05 was considered statistically 
significant in each case. 
RESULTS 
Both the groups were comparable for demographic 
data (Table-1). The objective variables for anxiety 
which included VAS for anxiety, observer’s anxiety 
criteria and sedation score were all significantly better 
(p<0.05) in patients who received midazolam when 
compared to the placebo group (Table-2). When 
systolic and diastolic blood pressures were compared 
between the two groups, they were significantly lower 
in the midazolam group after pre-medication (p<0.05) 
whereas there was no statistically significant change in 
the heart rate after pre-medication in either group 
(Table-3). Platelet aggregation profile was also similar 
among the two groups before and after pre-medication 
(Table-2). 
Table-1: Demographic data 
 Group-I Group-II p-value 
Age  
Weight  
Height 
42.67±5.64 
63.69±9.39 
153.57±11.27 
44.24±6.33 
60.37±16.26 
156.22±14.06 
NS 
NS 
NS 
NS= not significant 
Table-2: Visual analogue, observers anxiety, 
sedation score and platelet aggregation profile 
 Before drug After drug p–value 
Visual Analogue Scale for Anxiety 
Group I 3.49±1.51 3.50±1.33 NS 
Group II 3.06±1.34 2.01±1.38 <0.05 
Observer’s anxiety Criteria 
Group I 1.92±0.97 1.94±0.92 NS 
Group II 1.74±0.73 1.13±0.69 <0.05 
Sedation Score 
Group I 0.36±0.18 0.47±0.15 NS 
Group II 0.67±0.31 1.72±0.56 <0.05 
Platelet aggregation profile 
Group I 14.51±5.68 13.75±5.96 NS 
Group II 15.35 ± 7.92 14.02 ± 6.53 NS 
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Table-3: Haemodynamics   
 GROUP I GROUP II p–value 
SBP Before drug 
SBP After drug 
130.83±13.74 
134.71±15.49 
127.31±11.97 
112.83±11.39 
N.S 
<0.05 
DBP Before drug 
DBP After drug 
81.25±8.64 
84.17±8.66 
82.52±8.77 
72.13±6.74 
N.S 
<0.0 
HR Before drug 
HR After drug 
78.24±6.54 
78.31±6.32 
80.87±8.29 
82.32±6.58 
N.S 
N.S 
SBP= Systolic blood pressure, DBP= Diastolic blood pressure, 
HR= Heart Rate 
DISCUSSION 
Pre-medication traditionally has been used to achieve 
several goals including reduction of anxiety, 
preamptive analgesia, antisialogogue effect, 
provision of sedation etc, but the primary purpose of 
prescribing these drugs in the immediate preoperative 
period is to allay patient’s anxiety. Midazolam is an 
imidazobenzodiazepine that is rapidly and almost 
completely absorbed after oral administration.12 It has 
important hypnotic with anxiolytic properties that 
makes it very useful as a pre-medication drug.5 We 
have performed a double blind, randomized, placebo 
controlled study to assess the anxiolytic effect of 
midazolam as pre-medication subjectively, 
objectively and biochemically. The significant 
reduction in subjective assessment of anxiety level, 
both by the patient and the observer, after the 
administration of midazolam is in consistence with 
the previous studies.9,10 Sedation was also 
significantly better in the midazolam group as also 
shown in previous studies. We also measured the 
haemodynamic parameters including systolic blood 
pressure, diastolic blood pressure and heart rate as 
objective indicators of anxiolysis. In this study, there 
was a statistically significant reduction in both the 
systolic and diastolic blood pressures in the 
midazolam group whereas the heart rate increased 
clinically, but not statistically, in patients 
premedicated with midazolam. Midazolam have 
distinct effect on the cardiovascular system including 
a decrease in myocardial contractility, systemic 
vascular resistance and venodilation, all of which 
result in a fall in arterial blood pressure. This fall in 
systemic vascular resistance and venodilation leads to 
reduction in cardiac filling pressure, which further 
reduces the cardiac output. In response the 
baroreceptor reflex arc is activated which causes the 
heart rate to increase proportionately to compensate 
for the fall in cardiac output.11 The results of our 
study are consistent with previous studies6 but there 
is a difference in the magnitude of heart rate effect. In 
our study the rise in heart rate was less as compared 
to these studies which have quoted a rise in heart rate 
of up to 18%. The probable reason for this difference 
could a difference in patient population and low 
preoperative anxiety levels. Further studies are 
required to evaluate this effect in detail. There was no 
statistically significant difference in the platelet 
aggregation profile among the groups in our study 
which is contrary to the results of previous studies 
done on other drugs of benzodiazepine group. They 
all showed an increase in platelet aggregation when 
exposed to exogenous epinephrine.13,14 There are 
several factors which influence the platelet 
aggregation profile including age of plasma after 
venipuncture, pH of plasma, platelet count of platelet 
rich plasma, drugs ingested by patients, quality of 
reagent and patient’s age and sex.15 Many of the 
above mentioned variables were not standardised in 
our study which might have affected the platelet 
aggregation profile in our study. We also used sweet 
syrup to dissolve placebo and midazolam which 
could have resulted in a rise in serum glucose levels. 
It is known that increased level of glucose increases 
spontaneous platelet aggregation, independent of 
other factors, therefore the results obtained in our 
study may not be reflecting the true picture of platelet 
aggregation.13 In this study, platelet aggregation 
profile was obtained within an hour of collection of 
venous blood. Hardeman14 showed transient 
aggregation resistance of human blood platelets in 
fresh plasma if the test is done within an hour of 
venipuncture, this being another factor responsible 
for adverse platelet aggregation profile. 
CONCLUSION 
In conclusion midazolam 0.15 mg orally one hour 
before surgery is a suitable pre-medication to allay 
anxiety when clinical and objective criteria are used. 
The effect of midazolam on platelet aggregation 
needs to be further evaluated with better controlled 
trials attempting to maintain most of the variables 
constant. 
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